Table VI.

Co-expression of survivin and PTEN in endometrial carcinomas according to sum of stain intensity and scores of immunopositive cells in relation to clinopathological parameters.

Characteristics	Patients with either survivin or PTEN ++ expression, n (%)	Patients with survivin and PTEN +++ expression, n (%)	P-value
Age, years
<60	17 (29.8)	1 (50.0)	0.101
≥60	40 (70.2)	1 (50.0)
Histological type
Endometrioid	54 (94.7)	1 (50.0)	0.020
Clear cell and papillary serous	3 (5.3)	1 (50.0)
Clinical stage
I	40 (80.0)	2 (100.0)	0.837
II	7 (14.0)	0 (0.0)
III	3 (6.0)	0 (0.0)
Histological differentiation
G1	12 (21.1)	0 (0.0)	0.363
G2	32 (56.1)	1 (50.0)
G3	13 (22.8)	1 (50.0)
Myometrial invasion
<1/2	18 (31.6)	0 (0.0)	0.425
≥1/2	39 (68.4)	2 (100.0)
Lymph-vascular space invasion
Yes	8 (21.6)	1 (50.0)	0.272
No	29 (78.4)	1 (50.0)
Fallopian tube and/or ovarian invasion
Yes	10 (34.5)	0 (0.0)	0.352
No	19 (65.5)	0 (0.0)
Tumoral necrosis
Yes	5 (14.7)	0 (0.0)	0.687
No	29 (85.3)	0 (0.0)

P<0.05, statistically significant results; 0.05<P<0.10, suggestive results. PTEN, phosphatase and tensin homolog.